|
1) Shimizu K, Nagura E, Takatsuki K. Management of patients with multiple myeloma in Japan: Data of 1, 383 patients from 16 hospitals and 1 treatment group. Leuk Lymph. 2004; 45: 2465-9
|
|
|
|
|
2) Damiano JS, Cress AE, Hazlehurst LA, et al. Cell adhesion mediated drug resistance (CAM-DR): Role of integrins and resistance to apoptosis in human myeloma cell lines. Blood. 1999; 93: 1658-67
|
|
|
|
|
3) Hazlehurst LA, Argilagos RF, Emmons M, et al. Cell adhesion to fibronectin (CAM-DR) influences acquired mitoxantrone resistance in U937 cells. Cancer Res. 2006; 66: 2338-45
|
|
|
|
|
4) Hideshima T, Mitsiades C, Tonon G, et al. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer. 2007; 7: 585-98
|
|
|
|
|
|
5) 古川雄祐, 菊池次郎. 骨髄腫幹細胞と微小環境. 最新医学. 2008; 63: 2375-80
|
|
|
|
|
6) Cheung WC, Van Ness B. Distinct IL-6 signal transduction leads to growth arrest and death in B cells or growth promotion and cell survival in myeloma cells. Leukemia. 2002; 16: 1182-8
|
|
|
|
|
|
7) Hideshima T, Chauhan D, Hayashi T, et al. The biological sequelae of stromal cell-derived factor-1α in multiple myeloma. Mol Cancer Ther. 2002: 1: 539-44
|
|
|
|
|
|
8) Tai Y-T, Catley LP, Mitsiades CS, et al. Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human multiple myeloma cells: Clinical implications. Cancer Res. 2004; 64: 2846-52
|
|
|
|
|
|
9) Silvestris F, Cafforio P, Nalvani N, et al. Impaired osteoblastogenesis in myeloma bone disease: Role of upregulated apoptosis by cytokines and malignant plasma cells. Br J Haematol. 2004; 126: 475-86
|
|
|
|
|
|
10) Chang H, Samiee S, Yi QL. Prognostic relevance of CD56 expression in multiple myeloma: A study including 107 cases treated with high-dose melphalan-based chemotherapy and autologous stem cell transplant. Leuk Lymph. 2006; 47: 43-7
|
|
|
|
|
|
11) Yang Y, Yaccoby S, Liu W, et al. Soluble syndecan-1 promotes growth of myeloma tumors in vivo. Blood. 2002; 100: 610-7
|
|
|
|
|
|
12) Noborio-Hatano K, Kikuchi J, Takatoku M, et al. Bortezomib overcomes cell adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma. Oncogene. 2009; 28: 231-42
|
|
|
|
|
|
13) 菊池次郎, 古川雄祐. ボルテゾミブによる骨髄腫細胞のVLA-4発現抑制. 血液・腫瘍科. 2009; 59: 315-20
|
|
|
|
|
|
14) Matsunaga T, Takemoto N, Sato T, et al. Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia. Nat Med. 2003; 9: 1158-65
|
|
|
|
|
|
15) Duechler M, Shehata M, Schwarzmeier JD, et al. Induction of apoptosis by proteasome inhibitors in B-CLL cells is associated with downregulation of CD23 and inactivation of Notch2. Leukemia. 2005; 19: 260-7
|
|
|
|
|
|
16) Mori Y, Shimizu N, Dallas M, et al. Anti-α4 integrin antibody suppresses the development of multiple myeloma and associated osteoclastic osteolysis. Blood. 2004; 104: 2149-54
|
|
|
|
|
|
17) Olson DL, Burkly LC, Leone DR, et al. Anti-α4 integrin monoclonal antibody inhibits multiple myeloma growth in a murine model. Mol Cancer Ther. 2005; 4: 91-9
|
|
|
|
|
|
18) Schmidmaier R, Morsdorf K, Baumann P, et al. Evidence for cell adhesion-mediated drug resistance of multiple myeloma cells in vivo. Int J Biol Markers. 2006; 21: 218-22
|
|
|
|
|
|
19) Hazlehurst LA, Damiano JS, Buyuksal I, et al. Adhesion to fibronectin via β1 integrins regulates p27 kip1 levels and contributes to cell adhesion mediated drug resistance (CAM-DR). Oncogene. 2000; 19: 4319-27
|
|
|
|
|
|
20) Nefedova Y, Cheng P, Alsina M et al. Involvement of Notch-1 signaling in bone marrow stroma-mediated de novo drug resistance of myeloma and other malignant lymphoid cell lines. Blood. 2004; 103: 3503-10
|
|
|
|
|
|
21) Jundt F, Probsting KS, Anagnostopoulos I, et al. Jagged1-induced Notch signaling drives proliferation of multiple myeloma cells. Blood. 2004; 103: 3511-5
|
|
|
|
|
|
22) Landowski TH, Olashaw NE, Agrawal D, et al. Cell adhesion-mediated drug resistance (CAM-DR) is associated with activation of NF-κB (RelB/p50) in myeloma cells. Oncogene. 2003; 22: 2417-21
|
|
|
|
|
|
23) Chauhan D, Uchiyama H, Akbarali Y, et al. Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-κB. Blood. 1996; 87: 1104-12
|
|
|
|
|
|
24) Hazlehurst LA, Argilagos RF, Dalton WS, et al. β1-integrin mediated adhesion increases Bim protein degradation and contributes to drug resistance in leukaemia cells. Br J Haematol. 2006; 136: 269-75
|
|
|
|
|
|
25) Bellamy WT, Dalton WS, Gleason MC, et al. Development and characterization of a melphalan-resistant human multiple myeloma cell line. Cancer Res. 1991; 51: 995-1002
|
|
|
|
|
|
26) Chen Q, Van der Sluis PC, Boulware D, et al. The FA/BRCA pathway is involved in melphalan-induced DNA interstrand cross-link repair and accounts for melphalan resistance in multiple myeloma cells. Blood. 2005; 106: 698-705
|
|
|
|
|
|
27) Hazlehurst LA, Argilagos RF, Emmons M, et al. Cell adhesion to fibronectin (CAM-DR) influences acquired mitoxantrone resistance in U937 cells. Cancer Res. 2006; 66: 2338-45
|
|
|
|
|
|
28) Hazlehurst LA, Enkemann SA, Beam CA, et al. Genotypic and phenotypic comparisons of de novo and acquired melphalan resistance in an isogenic multiple myeloma cell line model. Cancer Res. 2003; 63: 7900-6
|
|
|
|
|
|
29) Ransohoff RM. Natalizmab for multiple sclerosis. N Engl J Med. 2007; 356: 2622-9
|
|
|
|
|
|
30) Krumbholz M, Meinl I, Kumpfel T, et al. Natalizmab disproportionally increases circulating pre-B and B cells in multiple sclerosis. Neurology. 2008; 71: 1350-4
|
|
|
|
|
|
31) Voorhees PM, Chen Q, Kuhn DJ, et al. Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma. Clin Cancer Res. 2007; 13: 6469-78
|
|
|
|
|
|
32) Devine SM, Flomenberg N, Vesole DH, et al. Rapid mobilization of CD34＋ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin's lymphoma. J Clin Oncol. 2004; 22: 1095-102
|
|
|
|
|
|
33) Azab AK, Runnels JM, Pitsillides C, et al. CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. Blood. 2009; 113: 4341-51
|
|
|
|
|